Dr. Reddy’s Laboratories to acquire OctoPlus for €27.4m

Published: 22-Oct-2012
Drug Delivery Finance Pharmaceutical

Aims to build a research base in Leiden, The Netherlands


Indian pharmaceuticals manufacturer Dr Reddy’s Laboratories is to acquire Netherlands-based drug delivery technology firm OctoPlus for about €27.4m in cash in its aim to globalise its R&D.

Dr Reddy’s currently holds a commitment from shareholders representing more than 50% of OctoPlus’s issued and outstanding shares. The executive board and the supervisory board of OctoPlus have unanimously recommended the offer to the remaining shareholders.

‘As we globalise our R&D efforts, we are looking forward to build a research base in Leiden, The Netherlands. The acquisition helps us ramp up our technology capabilities in drug delivery,’ said G V Prasad, vice-chairman and CEO of Dr Reddy’s.

The transaction should be concluded by the end of the current fiscal year.

  • Companies:
  • OctoPlus
  • Dr Reddys Laboratories
See more

You may also like

Manufacturing

Aurigene expands CDMO facilities for viral vectors

Read more
The facility allows for maximum flexibility for a multi-product, multi-platform offering across therapeutic proteins, antibodies, and viral vectors

Trending Articles

  1. Lonza Capsules & Health Ingredients expands capsule manufacturing capacity in India and China New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari (IN) and Suzhou (CN), highlighting the long-term strategic commitment to the business and the APAC region
  2. Novo Holdings completes acquisition of Catalent Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark
  3. ACG expands global footprint with new capsule manufacturing facility in Thailand New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets
  4. Newcells Biotech raises additional funding from investors Newcells Biotech, a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes, has raised a further £1.2m from existing investors Mercia Ventures, Northstar Ventures and North East Finance
  5. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Manufacturing

Aurigene expands CDMO facilities for viral vectors

The facility allows for maximum flexibility for a multi-product, multi-platform offering across therapeutic proteins, antibodies, and viral vectors
Manufacturing

Big names announced for leading Pharma and Cleanroom conference

The Cleanroom Technology Conference and Manufacturing Chemist Live collaboration will take place on the 10-11 November. Delegate tickets are currently available
Manufacturing

Dr. Reddy’s and TR-Pharm announce strategic collaboration in Turkey

Dr. Reddy’s and TR-Pharm have entered into a strategic collaboration agreement to manufacture and commercialise a portfolio of biosimilar drugs in Turkey
Pharmaceutical

Indian generic manufacturers aim to enter the Japanese market

The penetration of generic drugs in Japan is a little more than 30% compared with more 80% in the US market
Pharmaceutical

Dr. Reddy’s to distribute three Amgen medicines in India

In the areas of oncology and cardiology
Research & Development

Dr Reddy’s raises its R&D spending

Biosimilars account for around 15–20% of the overall R&D spend, representing US$45–60m
Finance

Dr Reddy’s to buy allergies and respiratory franchises in India from UCB for €118m

Strengthens its presence in dermatology, respiratory and paediatrics medicines
Subscribe now